Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Johnson & Johnson has started construction of a new building on its Spring House, Pennsylvania campus that will become a center for discovery research and early clinical development upon its completion in 2009.
Subscribe to our email newsletter
The development will add approximately 150,000 square feet in new laboratory, clinical development and office space to its existing facilities. Under the plan, Johnson & Johnson Pharmaceutical Research & Development LLC will retain 680 existing jobs at the site, and expects to add another 120 jobs over the next three years.
More than 15 Johnson & Johnson products were discovered or developed at the site, including several of major prescription medicines, such as Topamax, Ultram and Ultracet. Johnson & Johnson said this investment in this research building ensures that the teams have a fully equipped, state of the art facility to continue conducting world-class research.
“The new facility will provide our east coast team with state of the art capabilities to accelerate drug discovery and early development programs, and continue our tradition of delivering new medicines and driving value for our patients,” said Paul Stoffels, company group chairman, Pharmaceutical R&D, Johnson & Johnson.